Does Duration of Neuropathic Pain Impact the Effectiveness of Pregabalin?

被引:13
作者
Perez, Concepcion [1 ]
Latymer, Mark [2 ]
Almas, Mary [3 ]
Ortiz, Marie [3 ]
Clair, Andrew [3 ]
Parsons, Bruce [3 ]
Varvara, Roxana [2 ]
机构
[1] Hosp Princesa, Pain Clin, Madrid, Spain
[2] Pfizer Ltd, Tadworth, Surrey, England
[3] Pfizer, New York, NY USA
关键词
neuropathic pain; pregabalin; pain duration; DIABETIC PERIPHERAL NEUROPATHY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; POSTHERPETIC NEURALGIA; EFFICACY; SAFETY; TOLERABILITY; MULTICENTER; MANAGEMENT; SLEEP;
D O I
10.1111/papr.12469
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
BackgroundPatients with chronic pain conditions such as neuropathic pain frequently experience delays in diagnosis and treatment. Ideally, all patients should be treated in a timely manner, but in those patients with more established disease it is important to know that approved treatments remain effective. MethodsThis was a pooled analysis of 19 randomized placebo-controlled trials of pregabalin for peripheral neuropathic pain conditions, including diabetic peripheral neuropathy, postherpetic neuralgia, and post-traumatic/postsurgical pain. Patients were divided into 5 pain duration categories based on time since onset of pain (< 6 months, 6 months to < 1 year, 1 year to < 2 years, 2 years to < 5 years, and 5 years). Mean change in pain score at endpoint, vs. placebo, was assessed for each category, together with changes in Patient Global Impression of Change (PGIC) responders (very much or much improved at endpoint). ResultsThe analysis included 5,783 patients (n = 3,619 pregabalin; n = 2,164 placebo). Mean baseline pain scores were similar across the pain duration categories (range 6.3 to 6.5). Pregabalin significantly improved pain score at endpoint, vs. placebo, in all patients together (treatment difference [95% confidence interval], -0.59 [-0.67, -0.52], P < 0.0001) and similarly in each pain duration category (P < 0.0001 for each). There were significantly more PGIC responders with pregabalin, vs. placebo, for all patients (45.0% vs. 30.9%, P < 0.0001) and each category separately (P < 0.001 for each). There were no consistent, significant differences in treatment response between the different pain duration categories. ConclusionsPregabalin significantly improves pain irrespective of the length of time since onset of neuropathic pain.
引用
收藏
页码:470 / 479
页数:10
相关论文
共 44 条
  • [1] Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial
    Arezzo, Joseph C.
    Rosenstock, Julio
    LaMoreaux, Linda
    Pauer, Lynne
    [J]. BMC NEUROLOGY, 2008, 8 (1)
  • [2] EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
    Attal, N.
    Cruccu, G.
    Baron, R.
    Haanpaa, M.
    Hansson, P.
    Jensen, T. S.
    Nurmikko, T.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (09) : 1113 - E88
  • [3] Clinical characteristics and economic costs of patients with painful neuropathic disorders
    Berger, A
    Dukes, EM
    Oster, G
    [J]. JOURNAL OF PAIN, 2004, 5 (03) : 143 - 149
  • [4] Effectiveness of Pregabalin as Monotherapy or Combination Therapy for Neuropathic Pain in Patients Unresponsive to Previous Treatments in a Spanish Primary Care Setting
    Blanco Tarrio, Emilio
    Galvez Mateos, Rafael
    Zamorano Bayarri, Enric
    Lopez Gomez, Vanessa
    Perez Paramo, Maria
    [J]. CLINICAL DRUG INVESTIGATION, 2013, 33 (09) : 633 - 645
  • [5] Evidence-based guideline: Treatment of painful diabetic neuropathy
    Bril, V.
    England, J.
    Franklin, G. M.
    Backonja, M.
    Cohen, J.
    Del Toro, D.
    Feldman, E.
    Iverson, D. J.
    Perkins, B.
    Russell, J. W.
    Zochodne, D.
    [J]. NEUROLOGY, 2011, 76 (20) : 1758 - 1765
  • [6] A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury
    Cardenas, Diana D.
    Nieshoff, Edward C.
    Suda, Kota
    Goto, Shin-ichi
    Sanin, Luis
    Kaneko, Takehiko
    Sporn, Jonathan
    Parsons, Bruce
    Soulsby, Matt
    Yang, Ruoyong
    Whalen, Ed
    Scavone, Joseph M.
    Suzuki, Makoto M.
    Knapp, Lloyd E.
    [J]. NEUROLOGY, 2013, 80 (06) : 533 - 539
  • [7] Choinière M, 2010, CAN J ANAESTH, V57, P539, DOI 10.1007/s12630-010-9305-5
  • [8] Practice parameter: Treatment of postherpetic neuralgia an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology
    Dubinsky, RM
    Kabbani, H
    El-Chami, Z
    Boutwell, C
    Ali, H
    [J]. NEUROLOGY, 2004, 63 (06) : 959 - 965
  • [9] Pregabalin for the treatment of postherpetic neuralgia - A randomized, placebo-controlled trial
    Dworkin, RH
    Corbin, AE
    Young, JP
    Sharma, U
    LaMoreaux, L
    Bockbrader, H
    Garofalo, EA
    Poole, RM
    [J]. NEUROLOGY, 2003, 60 (08) : 1274 - 1283
  • [10] Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy - Findings from seven randomized, controlled trials across a range of doses
    Freeman, Roy
    Durso-Decruz, Edith
    Emir, Birol
    [J]. DIABETES CARE, 2008, 31 (07) : 1448 - 1454